Stephanie Carrington | Investor Relations, Managing Director at ICR, Inc. |
Jan-Anders Karlsson | Chief Executive Officer |
Piers Morgan | Chief Financial Officer |
Lucy Codrington | Jefferies |
Liana Moussatos | Wedbush Securities |
Julian Harrison | BTIG |
Fang-Ke Huang | SunTrust Robinson Humphrey |
Neil Carnahan | Stifel |
Patrick Trucchio | Berenberg Capital |
Jens Lindqvist | Nplus1 Singer |
Thank you operator. Good morning or afternoon, depending on where you are and welcome to today's call to review Verona Pharma's results for the three and six months ended June 30, 2019. On this call, I am joined by Jan-Anders Karlsson, Chief Executive Officer and Piers Morgan, Chief Financial Officer.
I trust you have seen the press release that included the results for the three and six months ended June 30, 2019, as well as the operational update and the press release with the data from the Phase II study with a dry powder inhaler formulation of ensifentrine.
If you have not, the press releases are also available on the Investor Relations portion of Verona Pharma's website.